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Abstract. Background: It has been previously shown that
blockade of the type 1 insulin-like growth factor receptor
(IGF1R) signaling combined with mTOR inhibition
decreased neuroblastoma proliferation in vitro. MYC-N
inactivation occurs through phosphorylation by downstream
elements of the IGF1R signaling pathway. It was
hypothesized that inhibition of IGF1R signaling would
increase the inactivation of MYC-N. Materials and Methods:
BE-2(c) and IMR-32 neuroblastoma cell lines were treated
with varying concentrations of αIR3, rapamycin and
temsirolimus either alone or in combination and the
expression of MYC-N and phosphorylated MYC-N proteins
were evaluated by Western blotting. The number of apoptotic
cells was evaluated through cleaved caspase-3 expression.
Results: IGF1R signaling blockade in combination with
mTOR inhibition decreased MYC-N protein expression,
increased MYC-N phosphorylation and significantly
increased cleaved caspase-3 expression in treated cells.
Conclusion: The combination of rapamycin or temsirolimus
with αIR3 decreases MYC-N expression, increases MYC-N
phosphorylation and induces apoptosis in vitro which may
have clinical relevance to children with neuroblastoma. 
Neuroblastoma is the third most common solid tumor
occurring in children, and the treatment of metastatic disease
continues to be challenging (1). Several clinical and
pathological factors including age and stage at diagnosis,
histology of tumor, and amplification of MYC-N, an
oncogene, have been used to develop a risk stratification for
treatment and prognosis. Children with high risk disease
have survival rates of less than 40%  at five years, despite
aggressive multimodal treatment. Therefore, innovative
approaches to understanding the pathogenesis of the tumor,
and for treatment of the disease are required.
The pathogenesis of neuroblastoma has been related to the
expression of the type 1 insulin-like growth factor receptor
(IGF1R), the receptor tyrosine kinase that primarily mediates
IGF-I actions. Research has shown that IGF1R signaling can
be blocked by a specific monoclonal antibody, αIR3, which
in turn can disrupt MYC-N expression (2). Inhibition of a
portion of the IGF1R signaling pathway can also be
accomplished by other therapies, including rapamycin or
temsirolimus that targets mTOR (mammalian target of
rapamycin), a downstream element in the PI3 kinase/Akt
pathway. It has been previously shown that treatment of two
human neuroblastoma cell lines with αIR3 and either
rapamycin or temsirolimus decreases proliferation (3).
Previous research has also shown that mTOR inhibition
decreased MYC-N protein expression (4). 
The IGF1R signaling pathway also has a role in regulating
the post translational activity of MYC-N (5). The MYC-N
protein is inactivated by phosphorylation mediated by the
serine/threonine kinase GSK-3β (6), which in turn is under
inhibitory control by the AKT kinase, a downstream
component of the IGF1R signaling cascade. Previous
research demonstrates that increasing GSK-3β activity by
inhibiting PI-3 kinase results in decreased neuroblastoma
growth (7). Therefore, it appears that inhibition of IGF1R
signaling may reduce neuroblastoma proliferation by two
mechanisms: i) reducing cell cycle signaling leading to
reduced cell survival; and ii) by inactivating MYC-N. 
It was postulated that inhibition of IGF1R signaling, at the
IGF1R and at the downstream element mTOR would
decrease MYC-N protein expression and increase MYC-N
phosphorylation. It was also hypothesized that decreased
MYC-N protein expression would result in increased
apoptosis. Two MYC-N amplified cell lines, BE-2(c) and
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IMR-32, were chosen because the experimental questions
centered on the regulation of MYC-N, and MYC-N-
amplified cell lines represent the most challenging tumors to
current treatment modalities. The findings on the effects of
inhibition of IGF1R and mTOR signaling on MYC-N
expression and inactivation in these human neuroblastoma
cell lines are hereby reported.
Materials and Methods
Cells and reagents. The cryopreserved mycoplasma-negative cell
lines IMR-32 and BE-2(c) were purchased from the Lineberger
Comprehensive Cancer Center Tissue Culture Facility (University
of North Carolina, Chapel Hill, NC, USA). Both cell lines were
derived from human neuroblastoma tissue and are maintained by the
American Type Culture Collection (ATCC). The BE-2(c) line
contains 123 copies of the MYC-N gene (8), and the IMR-32 cell
line contains 25 copies of the MYC-N gene (9). 
Rapamycin and temsirolimus were purchased from Wyeth
Pharmaceuticals (Madison, NJ, USA). The monoclonal antibody,
αIR3, was a gift from Dr. Judson J.Van Wyk, University of North
Carolina at Chapel Hill, North Carolina. Alpha-MEM, fetal calf
serum, and penicillin/streptomycin (Invitrogen Corporation, Carlsbad,
CA, USA) were purchased from the UNC Lineberger Comprehensive
Cancer Center Tissue Culture Facility, University of North Carolina. 
Cell culture. The cells were grown at 37˚C, 5%  CO2 in Alpha MEM
supplemented with 10%  fetal bovine serum, 2 mM glutamine, and
penicillin/streptomycin (control medium, CM). Cells were seeded
into 2 mL of media in 6 well plates (Costar, Corning, NY, USA) at
5×105/mL, and incubated for 24 hours. After 24 hours, the media was
removed, and 2 mL of serum free media was added to each well.
After an additional 24 hours, the serum free media was removed, and
triplicate specimens were incubated in one of the following media:
CM (experimental control), CM plus 0.5 μg/mL monoclonal antibody
directed against human myoglobin (IgG) to serve as an isotypic
antibody control, CM plus rapamycin (1 ng/mL); CM plus αIR3 (0.5
μg/mL); CM plus rapamycin and αIR3 (1 ng/mL and 0.5 μg/mL
respectively); CM plus temsirolimus (10 ng/mL); or CM plus
temsirolimus and αIR3 (10 ng/mL and 0.5 μg/mL, respectively) for
24 or 48 hours. Cell lysates were made using MPER reagent and
HALT protease cocktail (Pierce Biochemical, Indianapolis, IN, USA)
according to the manufacturer’s protocol. Lysates were aliquoted and
stored frozen at –80˚C until used. Protein concentrations of lysates
were determined using the BCA (Pierce) method per the
manufacturer’s instructions.
Western blotting assay. Fifty micrograms of the cell lysates were
subjected to SDS-PAGE as previously described (10). A
polyclonal antibody to human MYC-N (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and a rabbit monoclonal
antibody to human phosphorylated MYC-N (Bethyl Laboratories,
Burlingame, CA, USA) were used as per the manufacturers’
protocols. Secondary antibodies included a horseradish
peroxidase (HRP)-labeled goat anti-rabbit antibody and a HRP-
labeled rabbit anti-mouse antibody (Amersham Biosciences,
Pistcataway, NJ, USA). Antibody binding was visualized using
the enhanced chemiluminescence (ECL) detection system
(Amersham) according to the manufacturer’s protocol. Digitally
captured images were subjected to densitometry to quantify
changes in expression using an Image Pro Plus (Media
Cybernetics, Silver Spring, MD, USA) computer imaging and
data analysis system. All samples were normalized to β-Tubulin
staining (Millipore Corp, Billerica, MA, USA). 
Apoptosis assays. Cells were plated at 1×105 cells/mL and allowed
to grow for four days (approximately 80-90%  confluent). Cells were
then serum starved for 24 hours, and then incubated with CM or CM
plus αIR3 (0.5 μg/mL); rapamycin (1 ng/mL); temsirolimus (10
ng/mL); αIR3 plus rapamycin (0.5 μg/mL and 1 ng/mL,
respectively); or αIR3 plus temsirolimus (0.5 μg/mL and 10 ng/mL,
respectively). After 24 hours, the cells were fixed, stained with
Cleaved Caspase 3 antibody (Cell Signaling Technology, Danvers,
MA, USA) and counted. Photomicrographs of each treatment group
were obtained and analyzed using Image Pro Plus.
Statistical analyses. Statistical analyses including one-way ANOVA
and student’s t-test were performed using the Sigma Stat program,
version 1 (Jandel Scientific, San Rafael, CA, USA). 
Results
Treatment with rapamycin or temsirolimus in combination
with αIR3 inhibits MYC-N expression. The expression of
MYC-N protein was evaluated by Western blotting analyses
24 and 48 hours after treatment with αIR3, rapamycin,
temsirolimus, or a combination of rapamycin or
temsirolimus and αIR3 in both the BE-2(c) and IMR-32
cell lines. When serum-starved BE-2(c) cells were
incubated with a combination of rapamycin or temsirolimus
and αIR3 for 48 hours, MYC-N expression decreased
compared to the untreated controls (Figure 1B, top panels).
Similar results were seen for the IMR-32 cell line, with
statistically significant inhibition of MYC-N protein seen at
24 and 48 hours when compared to untreated controls
(Figure 2B, top panels). 
Treatment with rapamycin or temsirolimus in combination
with αIR3 increases inactivation of MYC-N protein. The
abundance of phosphorylated MYC-N increased 48 hours
after treatment with a combination of rapamycin or
temsirolimus and αIR3 in both the BE-2(c) and IMR-32 cell
lines (Figure 1B and 2B, middle panels). Furthermore, when
phosphorylated MYC-N was calculated as a percentage of
total MYC-N (determined by sequentially hybridizing the
same blot with antibodies to phosphorylated MYC-N and
MYC-N), the percentage of inactivated phosphorylated
MYC-N was significantly increased 24 hours after treatment
with a combination of rapamycin or temsirolimus and αIR3
(30%  in untreated vs. 45-55%  in treated cells). At 48 hours
the percentage of phosphorylated MYC-N increased
significantly to 80-90%  of the total MYC-N in the IMR-32
cell line and to 50-60%  in the BE-2(c) cell line (Figures 1B
and 2B, lower panels). 
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Figure 1. BE-2(c) representative Western blot analyses for MYC-N and phosphorylated MYC-N expression. A) Western blotting of protein lysates extracted
from BE-2 (c) cells that were serum starved (serum starved) and then evaluated one or two days after treatment with CM (control); CM and αIR3 (αIR3);
CM and rapamycin (Rapamycin); CM and temsirolimus (Temsirolimus), or CM and a combination of αIR3 with either rapamycin or temsirolimus
(Combo). β-tubulin expression is shown as a loading control. B) Fold changes in MYC-N, phosphorylated MYC-N, and percent phosphorylated MYC-N
protein in BE-2(c) cells. Cells were serum starved and evaluated one (solid bars) or two days (cross-hatched bars) after treatment with rapamycin,
temsirolimus, or a combination of αIR3 with either rapamycin or temsirolimus as previously described, and compared to 24 hour controls. *=p<0.05. 
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Figure 2. IMR-32 representative Western blot analyses for MYC-N and phosphorylated N-MYC expression. A) Western blotting of protein lysates extracted
from IMR-32 cells that were serum starved (serum starved) and then evaluated one or two days after treatment with CM (control); CM and αIR3 (αIR3);
CM and rapamycin (Rapamycin); CM and temsirolimus (Temsirolimus), or CM and a combination of αIR3 with either rapamycin or temsirolimus
(Combo). β-tubulin expression is shown as a loading control. B) Fold changes in MYC-N, phosphorylated MYC-N, and percent phosphorylated MYC-N
protein in BE-2(c) cells. Cells were serum starved and evaluated one (solid bars) or two days (cross-hatched bars) after treatment with rapamycin,
temsirolimus, or a combination of αIR3 with either rapamycin or temsirolimus as previously described, and compared to 24 hour controls. *=p<0.05.
Treatment with rapamycin or temsirolimus in combination
with α IR3 increases apoptosis. mTOR blockade with
temsirolimus significantly increased expression (p<0.05) of
cleaved caspase three in BE-2(C) neuroblastoma cells
(Figure 2A). Furthermore, combination of rapamycin or
temsirolimus with αIR3 significantly increased expression
(p<0.01) of cleaved caspase-3 when compared to untreated
controls in BE-2(c) neuroblastoma cells. 
Similar results were obtained for IMR-32 cell cultures
with mTOR blockade using temsirolimus. Cell cultures
treated with αIR3, rapamycin or temsirolimus alone
evidenced significant increases in expression of cleaved
caspase three (Figure 3A). Furthermore, combination of
rapamycin or temsirolimus with αIR3 significantly
increased expression (p<0.05) of cleaved caspase-3 over
single treatment values. 
Discussion
This study demonstrated that inhibition of the IGF1R with a
specific monoclonal antibody decreased MYC-N expression
and increased MYC-N inactivation. Blockade of mTOR with
rapamycin or temsirolimus also exhibited similar results in
the two neuroblastoma cell lines studied. Concentrations of
rapamycin used in these experiments are comparable to those
which are currently achievable in children and are well
tolerated without major side-effects.
The role of IGF1R signaling in the post translational
regulation of MYC-N makes IGF1R function important to
understanding neuroblastoma pathophysiology. The
amplification of the oncogene MYC-N in neuroblastoma is
believed to shorten the cell cycle and inhibit apoptosis (11).
MYC-N expression, therefore, portends a poor prognosis
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Figure 3. Effect of αIR3 and rapamycin or temsirolimus on expression of
cleaved capsase-3 in BE-2 (c) neuroblastoma cells. A) BE-2 (C) cells
were treated with CM (control); CM and αIR3 (IR3); CM and
rapamycin (RAP); CM and a combination of αIR3 and rapamycin
(CBRap); CM and temsirolimus (TEM); or CM and a combination of
αIR3 and temsirolimus (CBTem) as previously described. The number
of cells expressing cleaved caspase-3 per mm2 are shown. *=p<0.05,
#=p<0.001. B) Representative photomicrographs showing cleaved
caspase three positive cells in each experimental group.
Figure 4. Affect of αIR3 and rapamycin or temsirolimus on expression of
cleaved capsase-3 in IMR-32 neuroblastoma cells. A) IMR-32 cells were
treated with CM (control); CM and αIR3 (IR3); CM and rapamycin
(RAP); CM and a combination of αIR3 and rapamcyin (CBRap); CM
and temsirolimus (TEM); or CM and a combination of αIR3 and
temsirolimus (CBTem) as previously described. The number of cells
expressing cleaved caspase-3 per mm2 are shown. *=p<0.05,
#=p<0.001. B) Representative photomicrographs showing cleaved
caspase-3 positive cells in each experimental group.
both in response to therapy and overall survival in children
with neuroblastoma (12). MYC-N is targeted for
degradation within the cell by phosphorylation through
GSK-3β (13). GSK-3β in turn is under inhibitory control
by Akt, which itself is a downstream element of IGF1R
signaling (14). Therefore, it was hypothesized that
inhibition of IGF1 signaling with αIR3 would release the
inhibitory control of Akt, thereby increasing the activity of
GSK-3β and the inactivation of MYC-N. Furthermore, since
mTOR activates eukaryotic translation initiation factor 4E
(eIF4e) which has effects on growth factors, cyclin D1 and
MYC-N, it was hypothesized that blockade of mTOR with
rapamycin or temsirolimus might also increase MYC-N
inactivation (15). 
Firstly evaluation of the effects of IGF1R and mTOR
blockade on MYC-N expression was performed. Western
analyses of BE-2(c) and IMR-32 cell lysates demonstrated
that treatment with αIR3 increased MYC-N protein at 24
hours, perhaps due to insufficient binding of the αIR3
antibody to the IGF1R at a concentration necessary to
produce an inhibitory effect on MYC-N production in the
first 24 hours. (Figure 1B, 2B top panel). Consistent with
this possibility, 48 hours after treatment with αIR3, the total
levels of MYC-N protein were comparable to day one
controls in the BE-2(c) cell line. 
When BE-2(c) cells were treated with rapamycin or
temsirolimus, the level of total MYC-N protein initially
increased when examined at 24 hours, perhaps owing to a
delay in the cells metabolizing the drugs. By 48 hours the
production of MYC-N protein decreased below temsirolimus
day one values, but was not statistically significant in the
rapamycin treatment group (Figure 1B, top panel).
Statistically significant decreases in total MYC-N protein
were evident for both combination treatments at 48 hours. 
IMR-32 cells treated with rapamycin and temsirolimus also
showed an increase in the level of total MYC-N protein 24
hours after treatment; however, 48 hours after treatment with
rapamycin the expression of MYC-N protein was significantly
reduced. A similar trend to decreased MYC-N protein
expression was seen in the temsirolimus treatment group.
When rapamycin or temsirolimus was combined with αIR3,
MYC-N protein expression was significantly decreased at both
24 and 48 hours after treatment in the IMR-32 neuroblastoma
cells. These results are in contrast to those of Misawa and
colleagues whose evaluation culminated after 3 hours (16).
Next investigated the possibility that inhibition of IGF1R
and/or mTOR would increase the amount of phosphorylated
MYC-N was investigated. In the BE-2(c) treated cells, a
combination of rapamycin or temsirolimus with αIR3
significantly increased phosphorylation of MYC-N protein
at 48 hours (Figure 1B, middle panel). Evaluation of IMR-
32 cells showed a more profound increase in MYC-N protein
phosphorylation, with most treatment groups showing
statistically significant increases at both 24 and 48 hours.
The difference in response is attributed to the decreased
amount of MYC-N gene amplification in IMR-32 cells when
compared to BE-2(c) cells. 
When examining the proportion of MYC-N that was
phosphorylated, it was found that the phosphorylated fraction
decreased in both cell lines when cells were allowed to grow in
control media for 48 hours. This result is consistent with the
function of MYC-N as an oncogene in neuroblastoma, allowing
cells to move rapidly through the cell cycle and avoid apoptosis.
After treatment with a combination of αIR3 and rapamycin or
temsirolimus the phosphorylated fraction was significantly
increased in both the BE-2(c) and IMR-32 cell lines. 
Given that IGF-I has functions as an anti-apoptotic factor
whether IGF1R blockade and mTOR inhibition increased
apoptosis in human neuroblastoma cells was then investigated.
Apoptosis was evaluated in each cell line by quantifying the
expression of cleaved caspase-3, a marker of apoptosis (17).
When BE-2(c) cells were treated with temsirolimus or a
combination of αIR3 with rapamycin or temsirolimus a
statistically significant increase in expression of cleaved
caspase three was identified (Figure 3A). Photomicrographs of
each treatment group were obtained, and are shown in Figure
3B. The IMR-32 cell line showed increased expression of
cleaved caspase-3 protein in all treatment groups (Figure 4A).
Given that the IMR-32 cell line has one fifth the amount of
MYC-N as the BE-2(c) cell line, it was postulated that the
different results in the cell lines were due to a more profound
inhibition of MYC-N in the IMR-32 cells. 
IGF1R blockade and mTOR inhibition decreased MYC-N
protein expression, increased MYC-N phosphorylation, and
increased apoptosis in two human neuroblastoma cell lines.
It is necessary to understand the regulation of IGF-1R
signaling and the complex interplay of the IGF-1R and
mTOR signaling pathways before the clinical role of MYC-
N phosphorylation in neuroblastoma can be elucidated. It is
hoped that these avenues of investigation will spawn the
development of novel therapeutics for neuroblastoma.
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